Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.18
-0.24 (-1.12%)
At close: Feb 27, 2026, 4:00 PM EST
21.35
+0.17 (0.80%)
After-hours: Feb 27, 2026, 6:00 PM EST
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$991,373
Market Cap
3.31B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Vera Therapeutics | 224 |
| Alumis | 223 |
DNLI News
- 2 days ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 22 days ago - Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript - Seeking Alpha
- 23 days ago - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - GlobeNewsWire
- 26 days ago - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - GlobeNewsWire
- 4 weeks ago - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - GlobeNewsWire
- 6 weeks ago - Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewsWire
- 2 months ago - Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment - Seeking Alpha